Understanding how tau protein is regulated in brain cells could lead to better treatments for Parkinson's and other neurological conditions. Researchers discovered that similar lncRNAs control the production of tau and other key proteins involved in brain function.
Parkinson's UK is investing £1.2 million in a project to refine a molecule that could be developed into a drug to protect dopamine-producing brain cells and slow down the progression of Parkinson's. The project aims to develop a treatment that can halt Parkinson's by boosting the function of brain cells' energy-producing mitochondria.
A double-blind clinical trial investigates the effectiveness of ondansetron, a cancer anti-sickness drug, in alleviating hallucinations in people with Parkinson's. The study aims to find new treatments for this challenging symptom, which affects 75% of UK Parkinson's patients.
A study found that NLX-112 reduced dyskinesia and improved movement symptoms in marmosets with Parkinson's-like symptoms. The results suggest that the drug has potential as a future treatment for people with Parkinson's, offering hope for those affected by debilitating movement problems.
Researchers have discovered a promising molecule, BT13, that may slow or stop Parkinson's disease. By increasing dopamine levels and protecting brain cells, BT13 has shown promise in treating the condition.
Researchers have identified a probiotic that slows and reverses the build-up of alpha-synuclein protein, which is associated with Parkinson's disease. The probiotic, Bacillus subtilis, produces chemicals that change how enzymes process specific fats, preventing toxic clumps from forming.
A new three-year project aims to test the impact of sleep, exercise and low levels of alcohol on the glymphatic system, a recently discovered pathway that removes waste products from the brain. The study may lead to treatments that can target an important cause of both Parkinson's and Alzheimer's.
A pioneering clinical trial will assess the safety and efficacy of cannabidiol (CBD) in alleviating hallucinations and delusions associated with Parkinson's-related psychosis. The study aims to determine whether CBD can correct abnormal brain functioning and improve quality of life for affected individuals.
Parkinson's UK is partnering with NRG Therapeutics to develop a potential drug that could safeguard dopamine cells and slow down the progression of Parkinson's. The partnership will support the identification of novel molecules to protect mitochondria within dopamine-producing cells.
Researchers have found that anle138b can reduce alpha-synuclein clumps, restore dopamine levels and stop the progression of Parkinson's. Early treatment may be crucial in stopping the condition in its tracks.
A pioneering clinical trial has shown promising effects on restoring brain cells damaged in Parkinson's. While the treatment did not significantly impact symptoms, it demonstrated significant improvements in brain scans, suggesting long-term beneficial effects may be possible.
Parkinson's UK is providing over $1 million in funding to Neurolixis to accelerate the development of a promising new drug for people with Parkinson's. The project aims to address L-DOPA-induced dyskinesia, a disabling side effect of long-term L-DOPA treatment.
Seven major pharmaceutical companies have signed up to a groundbreaking Parkinson's consortium aimed at accelerating the development of safe and effective therapies. The consortium will share data, expertise, and resources with leading academics and industry members to promote and develop new treatments for Parkinson's.
A stem cell study published in Stem Cell Reports has discovered that the GBA1 mutation creates problems with protein processing and recycling in cells, leading to an accumulation of alpha-synuclein. This excess protein is released into the brain, contributing to Parkinson's spread and symptoms.
A study published in The Lancet Neurology found that people with Parkinson's who took the oral drug rivastigmine were 45% less likely to fall and steadier when walking. This breakthrough treatment has the potential to improve quality of life for millions worldwide.
Scientists develop peptide that binds to misshapen α-synuclein protein, stopping toxic fibril formation and brain cell death. The research offers a potential new approach for slowing Parkinson's disease progression.